CDYL2
Chromodomain Y-like protein 2
Also known as: CDYL2_HUMAN, FLJ38866
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q8N8U2
- Gene
- CDYL2
- Ensembl
- ENSG00000166446
- Chromosome
- 16
- Canonical length
- 506 aa
- Protein class
- Predicted intracellular proteins
OverviewNCBI Gene
Predicted to enable transcription corepressor activity. Predicted to be involved in negative regulation of DNA-templated transcription. Predicted to be active in nucleus. [provided by Alliance of Genome Resources, Apr 2025]
Canonical amino-acid sequenceUniProt
506 residues, UniProt reviewed canonical sequence.
>Q8N8U2|CDYL2
1 MASGDLYEVE RIVDKRKNKK GKWEYLIRWK GYGSTEDTWE PEHHLLHCEE FIDEFNGLHM
61 SKDKRIKSGK QSSTSKLLRD SRGPSVEKLS HRPSDPGKSK GTSHKRKRIN PPLAKPKKGY
121 SGKPSSGGDR ATKTVSYRTT PSGLQIMPLK KSQNGMENGD AGSEKDERHF GNGSHQPGLD
181 LNDHVGEQDM GECDVNHATL AENGLGSALT NGGLNLHSPV KRKLEAEKDY VFDKRLRYSV
241 RQNESNCRFR DIVVRKEEGF THILLSSQTS DNNALTPEIM KEVRRALCNA ATDDSKLLLL
301 SAVGSVFCSG LDYSYLIGRL SSDRRKESTR IAEAIRDFVK AFIQFKKPIV VAINGPALGL
361 GASILPLCDI VWASEKAWFQ TPYATIRLTP AGCSSYTFPQ ILGVALANEM LFCGRKLTAQ
421 EACSRGLVSQ VFWPTTFSQE VMLRVKEMAS CSAVVLEESK CLVRSFLKSV LEDVNEKECL
481 MLKQLWSSSK GLDSLFSYLQ DKIYEVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CDYL2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.43
- Highest tissue expression
- 13 nTPM
Expression across tissuesHPA
Tissue
- cerebellum: 13 nTPM
- testis: 10 nTPM
- placenta: 10 nTPM
- prostate: 9.2 nTPM
- seminal vesicle: 5.7 nTPM
- bone marrow: 5.3 nTPM
Single-cell type
- endometrial glandular cells: 409 nCPM
- prostatic glandular cells: 363 nCPM
- sertoli cells: 216 nCPM
- renal collecting duct intercalated cells: 157 nCPM
- neutrophil progenitors: 121 nCPM
- brain excitatory neurons: 89 nCPM
Immune cell
- non-classical monocyte: 4 nTPM
- intermediate monocyte: 1 nTPM
- eosinophil: 0.5 nTPM
- basophil: 0.3 nTPM
- memory CD8 T-cell: 0.3 nTPM
- myeloid DC: 0.2 nTPM
Brain region
- midbrain: 65 nTPM
- cerebellum: 40 nTPM
- cerebral cortex: 33 nTPM
- pons: 30 nTPM
- hypothalamus: 29 nTPM
- basal ganglia: 26 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.6
- gnomAD pLI
- 0.02
- gnomAD missense Z
- -0.11
- DepMap mean gene effect
- 0.01
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Chromo/chromo shadow domain
- Enoyl-CoA hydratase/isomerase-like domain
- Enoyl-CoA hydratase, C-terminal
- Chromo-like domain superfamily
- Chromo domain, conserved site
- Chromo domain
- ClpP/crotonase-like domain superfamily
- Enoyl-CoA hydratase/isomerase and chromodomain-containing protein
- Enoyl-CoA hydratase/isomerase
- Chromo (CHRromatin Organisation MOdifier) domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of CDYL2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CDYL2 as an antibody target. Whether an autoantibody or antibody against CDYL2 could matter depends on whether native CDYL2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CDYL2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label CDYL2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...